{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:43:33Z","timestamp":1773409413896,"version":"3.50.1"},"reference-count":44,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We hypothesized that low-dose (550-cGy), single-exposure, high dose rate (30 cGy\/min) total body irradiation (TBI) with cyclophosphamide as conditioning for HLA-compatible unrelated donor (URD) bone marrow transplantation (BMT) would result in donor chimerism (DC) with a low risk for serious organ toxicity and treatment-related mortality (TRM). Twenty-six patients with good risk diagnoses (acute leukemia in first complete remission [CR] and chronic-phase chronic myelogenous leukemia [CML]) and 84 with poor risk diagnoses underwent this regimen and URD BMT. Unsorted marrow nucleated cells were assessed for chimerism using VNTR probes. All DC occurred in 78 (86%) of 91 evaluable patients at 1 or more follow-up points. Graft failure occurred in 7 (7.7%) patients. Fatal organ toxicity occurred in only 2% of patients. TRM rates through 2 years of follow-up were 19% and 42% in those with good and poor risk diagnoses, respectively. Overall and disease-free survival rates in the good risk group were 47% and 40%, respectively, and in the poor risk group they were 25% and 21%, respectively, at a median follow-up for living patients of 850 days (range, 354-1588 days). This regimen resulted in 100% DC in most patients undergoing URD BMT with a relatively low risk for fatal organ toxicity and TRM.<\/jats:p>","DOI":"10.1182\/blood-2003-07-2346","type":"journal-article","created":{"date-parts":[[2004,5,11]],"date-time":"2004-05-11T00:13:23Z","timestamp":1084234403000},"page":"3035-3041","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide"],"prefix":"10.1182","volume":"105","author":[{"given":"Mark","family":"Girgis","sequence":"first","affiliation":[{"name":"From the Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia; Department of Radiology, Division of Radiation Oncology; and Department of Pathology, Division of Laboratory Medicine, Siteman Cancer Center and Washington University School of Medicine, St Louis, MO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Hallemeier","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia; Department of Radiology, Division of Radiation Oncology; and Department of Pathology, Division of Laboratory Medicine, Siteman Cancer Center and Washington University School of Medicine, St Louis, MO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Blum","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia; Department of Radiology, Division of Radiation Oncology; and Department of Pathology, Division of Laboratory Medicine, Siteman Cancer Center and Washington University School of Medicine, St Louis, MO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randy","family":"Brown","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia; Department of Radiology, Division of Radiation Oncology; and Department of Pathology, Division of Laboratory Medicine, Siteman Cancer Center and Washington University School of Medicine, St Louis, MO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu-san","family":"Lin","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia; Department of Radiology, Division of Radiation Oncology; and Department of Pathology, Division of Laboratory Medicine, Siteman Cancer Center and Washington University School of Medicine, St Louis, MO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Khoury","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia; Department of Radiology, Division of Radiation Oncology; and Department of Pathology, Division of Laboratory Medicine, Siteman Cancer Center and Washington University School of Medicine, St Louis, MO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Tim","family":"Goodnough","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia; Department of Radiology, Division of Radiation Oncology; and Department of Pathology, Division of Laboratory Medicine, Siteman Cancer Center and Washington University School of Medicine, St Louis, MO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia; Department of Radiology, Division of Radiation Oncology; and Department of Pathology, Division of Laboratory Medicine, Siteman Cancer Center and Washington University School of Medicine, St Louis, MO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Devine","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia; Department of Radiology, Division of Radiation Oncology; and Department of Pathology, Division of Laboratory Medicine, Siteman Cancer Center and Washington University School of Medicine, St Louis, MO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marita","family":"Wehde","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia; Department of Radiology, Division of Radiation Oncology; and Department of Pathology, Division of Laboratory Medicine, Siteman Cancer Center and Washington University School of Medicine, St Louis, MO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Postma","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia; Department of Radiology, Division of Radiation Oncology; and Department of Pathology, Division of Laboratory Medicine, Siteman Cancer Center and Washington University School of Medicine, St Louis, MO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarti","family":"Oza","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia; Department of Radiology, Division of Radiation Oncology; and Department of Pathology, Division of Laboratory Medicine, Siteman Cancer Center and Washington University School of Medicine, St Louis, MO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"DiPersio","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia; Department of Radiology, Division of Radiation Oncology; and Department of Pathology, Division of Laboratory Medicine, Siteman Cancer Center and Washington University School of Medicine, St Louis, MO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Adkins","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia; Department of Radiology, Division of Radiation Oncology; and Department of Pathology, Division of Laboratory Medicine, Siteman Cancer Center and Washington University School of Medicine, St Louis, MO."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021219461506000_REF1","doi-asserted-by":"crossref","unstructured":"McGlave PB, Shu X-O, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. Blood. 2000;95:2219-2225.","DOI":"10.1182\/blood.V95.7.2219"},{"key":"2020021219461506000_REF2","doi-asserted-by":"crossref","unstructured":"Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15:1767-1777.","DOI":"10.1200\/JCO.1997.15.5.1767"},{"key":"2020021219461506000_REF3","doi-asserted-by":"crossref","unstructured":"Storb R, Raff RF, Appelbaum FR, et al. Fractionated versus single-dose total body irradiation at low and high dose rates to condition canine littermates for DLA-identical marrow grafts. Blood. 1994;83:3384-3389.","DOI":"10.1182\/blood.V83.11.3384.3384"},{"key":"2020021219461506000_REF4","unstructured":"Fyles GM, Messner HA, Lockwood G, et al. Long-term results of bone marrow transplantation for patients with AML, ALL, and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rate. Bone Marrow Transplant. 1991;8:453-463."},{"key":"2020021219461506000_REF5","doi-asserted-by":"crossref","unstructured":"Blum W, Brown R, Lin H-S, et al. Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity. Biol Blood Marrow Transplant. 2002;8:608-618.","DOI":"10.1053\/bbmt.2002.v8.abbmt080608"},{"key":"2020021219461506000_REF6","doi-asserted-by":"crossref","unstructured":"Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral blood cells from HLA identical relatives in patients with hematologic cancers. N Eng J Med. 2001;344:175-181.","DOI":"10.1056\/NEJM200101183440303"},{"key":"2020021219461506000_REF7","unstructured":"NIH Transplantation Immunology Branch Staff. Lymphocytotoxicity. In: NIAID Manual of Tissue Typing Techniques, 1976-1977. Washington, DC: Department of Health, Education, and Welfare. Publication (NIH) 76-545, p 22."},{"key":"2020021219461506000_REF8","unstructured":"Duffy BF, Begovich AB, Novotny JF, Mohanakumar T. Allele level HLA DRB typing with Amplicor (RELI\u2122) typing kit using an extended panel of primers and probes [abstract]. Human Immunol. 1997:55:137."},{"key":"2020021219461506000_REF9","doi-asserted-by":"crossref","unstructured":"Khoury H, Trinkaus K, Zhang MJ, et al. Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. Biol Blood Marrow Transplant. 2003;9:714-721.","DOI":"10.1016\/j.bbmt.2003.08.006"},{"key":"2020021219461506000_REF10","doi-asserted-by":"crossref","unstructured":"Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.","DOI":"10.1097\/00007890-197410000-00001"},{"key":"2020021219461506000_REF11","doi-asserted-by":"crossref","unstructured":"Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Hematol. 1997;97:855-864.","DOI":"10.1046\/j.1365-2141.1997.1112925.x"},{"key":"2020021219461506000_REF12","doi-asserted-by":"crossref","unstructured":"Shulman H, Sullivan K, Weiden P, et al. Chronic graft-versus-host syndrome in man. Am J Med. 1980;69:204-217.","DOI":"10.1016\/0002-9343(80)90380-0"},{"key":"2020021219461506000_REF13","unstructured":"Reed KC, Mann DA. Rapid transfer of DNA from agarose gels to nylon membranes. Nucl Acids Res. 1985;13:7202-7221."},{"key":"2020021219461506000_REF14","doi-asserted-by":"crossref","unstructured":"Wong Z, Wilson V, Patel I, Povey S, Jeffreys AJ. Characterization of a panel of highly variable minisatellites cloned from human DNA. Ann Hum Genet. 1987;51:269-288.","DOI":"10.1111\/j.1469-1809.1987.tb01062.x"},{"key":"2020021219461506000_REF15","unstructured":"NCI Common Toxicity Criteria, Version 2.0. Washington, DC: National Institutes of Health, National Cancer Institute, 1998."},{"key":"2020021219461506000_REF16","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"2020021219461506000_REF17","doi-asserted-by":"crossref","unstructured":"Niederwiser D, Maris M, Shizuru JA. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620-1629.","DOI":"10.1182\/blood-2002-05-1340"},{"key":"2020021219461506000_REF18","doi-asserted-by":"crossref","unstructured":"Spitzer TR, McAfee S, Sackstein R, et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant. 2000;6:309-320.","DOI":"10.1016\/S1083-8791(00)70056-5"},{"key":"2020021219461506000_","doi-asserted-by":"crossref","unstructured":"Antin JH, Childs R, Filipovich AH, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendatons from a workshop at the 2001 tandem meetings. Biol Blood Marrow Transplant. 2001;7:473-485.","DOI":"10.1053\/bbmt.2001.v7.pm11669214"},{"key":"2020021219461506000_","doi-asserted-by":"crossref","unstructured":"Michallet M, Karin B, Garban F, et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors and outcome. J Clin Oncol. 2001;19:3340-3349.","DOI":"10.1200\/JCO.2001.19.14.3340"},{"key":"2020021219461506000_","doi-asserted-by":"crossref","unstructured":"Spitzer TR. Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. Oncologist. 2000;5:215-223.","DOI":"10.1634\/theoncologist.5-3-215"},{"key":"2020021219461506000_REF22","doi-asserted-by":"crossref","unstructured":"Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1994;94:3234-3241.","DOI":"10.1182\/blood.V94.9.3234"},{"key":"2020021219461506000_REF23","doi-asserted-by":"crossref","unstructured":"Davies SM, Kollman C, Anasetti C, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program. Blood. 2000;96:4096-4102.","DOI":"10.1182\/blood.V96.13.4096"},{"key":"2020021219461506000_REF24","doi-asserted-by":"crossref","unstructured":"Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndrome: analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood. 2002;99:1943-1951.","DOI":"10.1182\/blood.V99.6.1943"},{"key":"2020021219461506000_REF25","doi-asserted-by":"crossref","unstructured":"Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021-2030.","DOI":"10.1182\/blood-2003-02-0482"},{"key":"2020021219461506000_REF26","unstructured":"Bornhau\u0308ser M, Thiede C, Platzbecker U, et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res. 2001;7:2254-2262."},{"key":"2020021219461506000_","doi-asserted-by":"crossref","unstructured":"Mackinnon S, Barnett L, Heller G, O'Reilly RJ. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood. 1994;83:3409-3416.","DOI":"10.1182\/blood.V83.11.3409.3409"},{"key":"2020021219461506000_","doi-asserted-by":"crossref","unstructured":"Roux E, Heig C, Chapuis B, Jeannet M, Roosnek E. Mixed chimerism after bone marrow transplantation and the risk of relapse [letter]. Blood. 1994; 84:4385-4386.","DOI":"10.1182\/blood.V84.12.4385.bloodjournal84124385"},{"key":"2020021219461506000_REF29","doi-asserted-by":"crossref","unstructured":"Wong R, Giralt S, Martin T, et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003;102:3052-3059.","DOI":"10.1182\/blood-2003-03-0855"},{"key":"2020021219461506000_REF30","doi-asserted-by":"crossref","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390-3400.","DOI":"10.1182\/blood.V97.11.3390"},{"key":"2020021219461506000_REF31","doi-asserted-by":"crossref","unstructured":"Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631-637.","DOI":"10.1182\/blood.V97.3.631"},{"key":"2020021219461506000_REF32","doi-asserted-by":"crossref","unstructured":"Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995;86:3979-3986.","DOI":"10.1182\/blood.V86.10.3979.bloodjournal86103979"},{"key":"2020021219461506000_REF33","doi-asserted-by":"crossref","unstructured":"Deeg HJ, Lin D, Leisenring W, et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood. 1997;89:3880-3887.","DOI":"10.1182\/blood.V89.10.3880"},{"key":"2020021219461506000_REF34","doi-asserted-by":"crossref","unstructured":"Sayer HG, Longton G, Bowden R, et al. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood. 1994;84:1328-1332.","DOI":"10.1182\/blood.V84.4.1328.1328"},{"key":"2020021219461506000_REF35","doi-asserted-by":"crossref","unstructured":"Remberger M, Ringden O, Blau IW, et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood. 2001;98:1739-1745.","DOI":"10.1182\/blood.V98.6.1739"},{"key":"2020021219461506000_","doi-asserted-by":"crossref","unstructured":"Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplantation. 2000;26:397-404.","DOI":"10.1038\/sj.bmt.1702519"},{"key":"2020021219461506000_REF37","doi-asserted-by":"crossref","unstructured":"Weisdorf DJ, Anasetti C, Antin J, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99:1971-1977.","DOI":"10.1182\/blood.V99.6.1971"},{"key":"2020021219461506000_REF38","unstructured":"Ferrant A, Labopin M, Frassoni F, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European group for blood and marrow transplantation study. Blood. 1997;90:2931-2938."},{"key":"2020021219461506000_","doi-asserted-by":"crossref","unstructured":"Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcomes in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.","DOI":"10.1182\/blood.V92.7.2322"},{"key":"2020021219461506000_REF40","doi-asserted-by":"crossref","unstructured":"Dombret H, Gaber J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2014results of the prospective multicenter LALA-94 trial. Blood. 2002;100:2357-2365.","DOI":"10.1182\/blood-2002-03-0704"},{"key":"2020021219461506000_REF41","doi-asserted-by":"crossref","unstructured":"Weisdorf DJ, Billett AL, Hannan P, et al. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood. 1997;90:2962-2968.","DOI":"10.1182\/blood.V90.8.2962"},{"key":"2020021219461506000_REF42","doi-asserted-by":"crossref","unstructured":"Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia with myeloablative therapy. Blood. 1997;89:4531-4536.","DOI":"10.1182\/blood.V89.12.4531"},{"key":"2020021219461506000_REF43","unstructured":"NMDP Overview 2001. Minneapolis, MN: National Marrow Donor Program; 2001. Available at: www.marrow.org. Accessed January 23, 2005."},{"key":"2020021219461506000_REF44","doi-asserted-by":"crossref","unstructured":"Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood. 2001;97:1572-1577.","DOI":"10.1182\/blood.V97.6.1572"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/8\/3035\/1709397\/zh800805003035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/8\/3035\/1709397\/zh800805003035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T03:32:20Z","timestamp":1585798340000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/8\/3035\/20586\/Chimerism-and-clinical-outcomes-of-110-recipients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,15]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,4,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-07-2346","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,15]]}}}